These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 17290060

  • 1. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.
    J Clin Oncol; 2007 Feb 10; 25(5):517-25. PubMed ID: 17290060
    [Abstract] [Full Text] [Related]

  • 2. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.
    Biomed Pharmacother; 2009 Sep 10; 63(8):553-60. PubMed ID: 18571892
    [Abstract] [Full Text] [Related]

  • 3. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.
    Gynecol Oncol; 2014 Jun 10; 133(3):591-8. PubMed ID: 24657486
    [Abstract] [Full Text] [Related]

  • 4. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Têtu B, Bachvarov D.
    Int J Oncol; 2006 Jul 10; 29(1):5-24. PubMed ID: 16773180
    [Abstract] [Full Text] [Related]

  • 5. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.
    Clin Cancer Res; 2005 Aug 15; 11(16):6030-9. PubMed ID: 16115948
    [Abstract] [Full Text] [Related]

  • 6. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H.
    Gynecol Oncol; 2009 Aug 15; 114(2):253-9. PubMed ID: 19446316
    [Abstract] [Full Text] [Related]

  • 7. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
    Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Müller-Holzner E, Marth C, Zeimet AG.
    Clin Cancer Res; 2007 Jan 01; 13(1):144-51. PubMed ID: 17200349
    [Abstract] [Full Text] [Related]

  • 8. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
    Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM.
    Gynecol Oncol; 2010 May 01; 117(2):170-6. PubMed ID: 20132968
    [Abstract] [Full Text] [Related]

  • 9. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, Kikuchi Y.
    Oncol Rep; 2006 May 01; 15(5):1265-71. PubMed ID: 16596196
    [Abstract] [Full Text] [Related]

  • 10. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
    Osterberg L, Levan K, Partheen K, Staaf J, Sundfeldt K, Horvath G.
    Cytogenet Genome Res; 2009 May 01; 125(1):8-18. PubMed ID: 19617691
    [Abstract] [Full Text] [Related]

  • 11. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M, Miyazaki K.
    Clin Cancer Res; 2008 May 15; 14(10):3149-55. PubMed ID: 18483383
    [Abstract] [Full Text] [Related]

  • 12. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
    Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, deFazio A.
    Clin Cancer Res; 2008 Nov 01; 14(21):6924-32. PubMed ID: 18980987
    [Abstract] [Full Text] [Related]

  • 13. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y, Wang J, Xiang D, Wang D, Xin X.
    Int J Oncol; 2009 Nov 01; 35(5):1069-79. PubMed ID: 19787261
    [Abstract] [Full Text] [Related]

  • 14. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
    Glinsky GV.
    J Clin Oncol; 2008 Jun 10; 26(17):2846-53. PubMed ID: 18539963
    [Abstract] [Full Text] [Related]

  • 15. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Jun 10; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 16. Expression profiling and individualisation of treatment for ovarian cancer.
    Agarwal R, Kaye SB.
    Curr Opin Pharmacol; 2006 Aug 10; 6(4):345-9. PubMed ID: 16750423
    [Abstract] [Full Text] [Related]

  • 17. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A.
    Crit Rev Oncol Hematol; 2009 Sep 10; 71(3):233-41. PubMed ID: 19179095
    [Abstract] [Full Text] [Related]

  • 18. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
    Györffy B, Serra V, Jürchott K, Abdul-Ghani R, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schäfer R.
    Oncogene; 2005 Nov 17; 24(51):7542-51. PubMed ID: 16044152
    [Abstract] [Full Text] [Related]

  • 19. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME.
    J Clin Oncol; 2008 Dec 01; 26(34):5530-6. PubMed ID: 18955455
    [Abstract] [Full Text] [Related]

  • 20. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M, Alberts DS, Garcia DJ, Emerson J, Fanta P, Liu R, Salmon SE.
    Gynecol Oncol; 1994 Dec 01; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.